跳至主要内容
临床试验/NCT00812188
NCT00812188已完成不适用

A Prospective, Open Label Trial of High Dose UVA-1, 3x/Week or Medium Dose UVA-1, 3x/Week vs. Fluocinonide 0.05% Cream Treatment of Morphea

University of Texas Southwestern Medical Center2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2004年11月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
24
试验地点
2
主要终点
Efficacy of UVA-1 treatment vs. topical steroid.

研究概览

简要总结

Compare UVA-1 phototherapy treatment to topical steroid treatment in subjects with morphea.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female subjects 18 years of age or older.
  • Symmetric limited morphea.

排除标准

  • Known sensitivity to fluocinonide 0.05% cream.
  • Clinical evidence of superinfected skin.
  • Immunocompromised state (including previously documented HIV).
  • Generalized Scleroderma.
  • Previous history of skin cancer.
  • Non-English speaking subjects.

研究组 & 干预措施

Medium Dose UVA-1

Active Comparator

Medium dose (60 J/cm2) UVA-1 3x/week for 12 weeks to one morphea plaque and fluocinonide 0.05% cream to another morphea plaque twice daily for twelve weeks.

干预措施: Medium Dose UVA-1 (Other)

High Dose UVA-1

Active Comparator

High dose UVA-1 treatment 3x/week for 12 weeks to one morphea plaque and fluocinonide 0.05% cream twice daily for 12 weeks to another morphea plaque.

干预措施: High Dose UVA-1 (Other)

结局指标

主要结局

Efficacy of UVA-1 treatment vs. topical steroid.

时间窗: 5 years

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Heidi Jacobe

Principal Investigator

University of Texas Southwestern Medical Center

研究点 (2)

Loading locations...

相似试验